Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IBI363 |
Trade Name | |
Synonyms | IBI-363|IBI 363 |
Drug Descriptions |
IBI363 is a bispecific antibody fusion protein comprised of a monoclonal antibody that targets PD-1 (PDCD1) linked to a modified form of IL-2, which potentially leads to decreased PD-1 signaling, elevated IL-2-dependent signaling, and restoration of the anti-tumor immune response (NCI Drug Dictionary). |
DrugClasses | PD-L1/PD-1 antibody 121 |
CAS Registry Number | NA |
NCIT ID | C189813 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IBI363 | IBI363 | 0 | 2 |